p21 Antikörper (pThr145)

Produktnummer ABIN362238

Produktdetails anti-p21 Antikörper

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Bindungsspezifität: pThr145

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser p21 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC)

Spezifität: The antibody detects endogenous level of p21Cip1 only when phosphorylated at threonine 145.

Aufreinigung: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.

Immunogen: Peptide sequence around phosphorylation site of pThr145 (R-Q-T (p) -S-M) derived from Human p21Cip1. Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Immunohistochemistry: 1:50-1:100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at -20 °C for long term preservation (recommended). Store at 4 °C for short term use.

Details zu p21

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Andere Bezeichnung: p21Cip1 (CDKN1A Produkte)

Synonyme: CCND1 antikoerper, CDKN1A antikoerper, CAP20 antikoerper, CDKN1 antikoerper, CIP1 antikoerper, MDA-6 antikoerper, P21 antikoerper, SDI1 antikoerper, WAF1 antikoerper, p21CIP1 antikoerper, CDKI antikoerper, Cdkn1 antikoerper, Waf1 antikoerper, mda6 antikoerper, p21Cip1 antikoerper, p21WAF antikoerper, Cip1 antikoerper, UV96 antikoerper, p21 antikoerper, cip1 antikoerper, p16Xic2 antikoerper, sdi1 antikoerper, waf1 antikoerper, cap20 antikoerper, cdkn1 antikoerper, mda-6 antikoerper, p21cip1 antikoerper, si:ch1073-48m5.2 antikoerper, KRAS2 antikoerper, p21ras antikoerper, cyclin D1 antikoerper, cyclin dependent kinase inhibitor 1A antikoerper, cyclin-dependent kinase inhibitor 1A (P21) antikoerper, cyclin-dependent kinase inhibitor 1A antikoerper, cyclin-dependent kinase inhibitor 1A L homeolog antikoerper, cyclin-dependent kinase inhibitor 1 antikoerper, KRAS proto-oncogene, GTPase antikoerper, CCND1 antikoerper, CDKN1A antikoerper, Cdkn1a antikoerper, cdkn1a.L antikoerper, cki1 antikoerper, cdkn1a antikoerper, KRAS antikoerper

Hintergrund: May be the important intermediate by which p53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression.

Molekulargewicht: 21 kDa

UniProt: P38936

Pathways: p53 Signalweg, PI3K-Akt Signalweg, Zellzyklus, AMPK Signaling, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Mitotic G1-G1/S Phases, DNA Replication, Hepatitis C, Synthesis of DNA, Autophagie